TransMedics raises 2026 revenue guidance after Q3 revenue jumps 41% with strong growth and new FDA trial approvals

TransMedics Group reported a 41% revenue increase to $203 million in Q3 2026, driven by growth in organ transplant products and services. The company raised its full-year 2026 revenue guidance to $764-$774 million, including contributions from its new PAD Aviation logistics service. Recent FDA approvals for clinical trials and expansion into European markets position TransMedics for continued growth. The company expects further catalysts in 2027 with new trials and product launches targeting heart, lung, and kidney transplants.

TransMedics Group shares trade at USD 80.50 on Pluang as of Nov 06, 2026 04:11 WIB, up 10.65% in one day. The stock's market cap stands at $2.52 billion with a 52-week range between $61.99 and $150.42. Pluang investors show full buying interest with 100% buy orders and a typical hold time of 26 days.